Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4930135 | 0.96 | P2RX3 (0.46) | P2RX3NPC1RAB9ASMN1; SMN2CACNA2D1 | |
| SCHEMBL4930949 | 0.94 | P2RX3 (0.42) | P2RX3NPC1RAB9ASMN1; SMN2CACNA2D1 | |
| SCHEMBL4929846 | 0.92 | P2RX3 (0.41) | P2RX3NPC1RAB9ASMN1; SMN2CACNA2D1 | |
| SCHEMBL4928512 | 0.92 | SMN1; SMN2 (0.46) | P2RX3NPC1RAB9ASMN1; SMN2CACNA2D1 | |
| SCHEMBL4928429 | 0.92 | NPC1 (0.53) | P2RX3NPC1RAB9ASMN1; SMN2CACNA2D1 | |
| SCHEMBL4922200 | 0.91 | P2RX3 (0.46) | P2RX3NPC1RAB9ASMN1; SMN2CACNA2D1 | |
| SCHEMBL4927663 | 0.90 | P2RX3 (0.42) | P2RX3NPC1RAB9ASMN1; SMN2CACNA2D1 | |
| SCHEMBL4924570 | 0.88 | P2RX3 (0.41) | P2RX3NPC1RAB9ASMN1; SMN2CACNA2D1 | |
| SCHEMBL4930067 | 0.88 | SMN1; SMN2 (0.46) | P2RX3NPC1RAB9ASMN1; SMN2CACNA2D1 | |
| SCHEMBL4929856 | 0.87 | P2RX3 (0.46) | P2RX3NPC1RAB9ASMN1; SMN2CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1810677-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-1810677-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021069-A1 | Receptor Function Regulating Agent | GPR119, INSR, GPR65 | P2RX3 463/4885NPC1 1300/4885RAB9A 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.